The release of NGF by cancer cells (Sevcik et al., 2005) and the NGF-induced sensitisation of primary afferent nerves in the tumour-laden bone (Pantano et al., 2011) highlight potential mechanisms for pain relief with anti-NGF antibodies. Here, NGF is linked to neoplasm.